Two patients with non-small cell lung cancer presented with multiple brain metastases. They received gefitinib orally for the treatment of the primary lung lesions. About one month later, the brain metastases unexpectedly disappeared or became smaller. The patients survived without recurrence of brain metastases and growth of lung lesions for 3-4 years. Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor and is approved for use in the treatment of non-small cell lung cancer. Gefitinib may be very effective for multiple brain metastases in patients with non-small cell lung cancer.

译文

:两名非小细胞肺癌患者出现多发性脑转移。他们口服吉非替尼治疗原发性肺部病变。大约一个月后,脑转移意外消失或变小。患者存活了3-4年,没有脑转移复发和肺部病变的增长。吉非替尼是一种选择性的表皮生长因子受体酪氨酸激酶抑制剂,被批准用于治疗非小细胞肺癌。吉非替尼对非小细胞肺癌患者的多发性脑转移可能非常有效。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录